Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk

Dow Jones

2024-12-19

1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a "buy the rumor, sell the news," reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com)

(END) Dow Jones Newswires

December 18, 2024 13:49 ET (18:49 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492378861"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492378861\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492378861?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 02:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492378861","market":"us","top_or_hot":-1,"title":"Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 13:49 ET (18:49 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-19 02:49</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 13:49 ET (18:49 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492378861","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492378861","pubTimestamp":1734547740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"尽管首席执行官发表乐观言论，Corvus Pharmaceuticals仍暴跌——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a \"buy the rumor, sell the news,\" reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 13:49 ET (18:49 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}